NVON Stock Chart & Stats
$798.51
$2.02(0.24%)
At close: 4:00 PM EDT
$798.51
$2.02(0.24%)
Day’s Range― - ―
52-Week Range$637.43 - $1,140.00
Previous CloseN/A
Volume2.60K
Average Volume (3M)10.65K
Market Cap
$3.34T
Enterprise Value$227.20K
Total Cash (Recent Filing)$44.98B
Total Debt (Recent Filing)$140.13B
Price to Earnings (P/E)10.5
Beta0.10
Next Earnings
Nov 04, 2026EPS Estimate
13.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)26.23
Shares Outstanding3,390,128,000
10 Day Avg. Volume20,935
30 Day Avg. Volume10,651
Financial Highlights & Ratios
PEG Ratio8.16
Price to Book (P/B)7.42
Price to Sales (P/S)4.66
P/FCF Ratio49.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$747.82Price Target Upside-6.35% Downside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)57.96
Revenue Forecast (FY)$784.76B
Bulls Say, Bears Say
Bulls Say
Exceptional Growth And ProfitabilityNovo Nordisk combines exceptional revenue growth with best-in-class profitability, demonstrating strong demand and substantial operating leverage. These economics can support continued investment in capacity, research and commercial expansion while preserving meaningful earnings power over the next several quarters.
Recurring Chronic-care DemandThe company serves chronic metabolic diseases through branded medicines that patients typically use on a recurring basis. This creates a more durable revenue foundation than episodic treatment models, while its diabetes, obesity and rare-disease portfolio broadens exposure across ongoing healthcare needs.
Expanding Obesity FranchiseRapid Wegovy pill adoption and continued launches across markets strengthen Novo Nordisk’s obesity franchise and extend its global commercial reach. Regulatory approvals for pill and high-dose formulations also expand the product platform, supporting longer-term growth despite a more competitive market.
Bears Say
Rising LeverageDebt has increased substantially faster than the prior baseline, raising leverage and reducing financial flexibility. Although earnings power remains strong, continued borrowing at this pace could constrain capital allocation and make the business less resilient if product cycles or industry conditions weaken.
Weak Free-cash-flow ConversionOperating cash generation is healthy, but only a small portion of accounting profit converted into free cash flow on a trailing basis. Higher capital spending or working-capital needs reduce the cash cushion available for reinvestment, debt management and shareholder distributions over coming quarters.
Pipeline Setback And Concentration RiskThe failed ZEUS outcome weakens one part of the development pipeline, while increasing reliance on GLP-1 products concentrates future earnings exposure. That combination heightens sensitivity to competition, pricing and regulatory changes affecting the company’s leading franchise.
Novo Nordisk News
NVON FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $637.43 and its highest was $1140.00 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $3.34T.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Nov 04, 2026 which is in 53 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Aug 04, 2026. The company reported $16.206 earnings per share for the quarter, beating the consensus estimate of $13.067 by $3.139.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Overvalued.
Does Novo Nordisk pay dividends?
Novo Nordisk does not currently pay dividends.
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 13.05.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $16.206 in its last earnings report, beating expectations of $13.067. Following the earnings report the stock price went down -6.432%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in MX:NVON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novo Nordisk Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$747.82 (-6.35% Downside)
$747.82 (-6.35% Downside)
Blogger Sentiment
Bullish
MX:NVON Sentiment 71%
Sector Average 62%
Sector Average 62%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.98%
12-Months-Change
Fundamentals
Return on Equity
4.19%
Trailing 12-Months
Asset Growth
19.95%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Novo Nordisk
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
NVON Company Deck
NVON Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights very strong commercial and clinical momentum—especially for the Wegovy franchise (oral and high‑dose launches), positive pivotal and Phase II readouts (Etavopivat, UBT251), significant prescription uptake and clear execution on launches and shareholder returns. However, these commercial and R&D successes are balanced by meaningful near‑term financial headwinds: adjusted sales and operating profit declines, margin pressure from lower realized prices, pricing and reimbursement pressures (U.S. and international), guidance implying negative group growth for 2026, and supply/inventory nuances. Overall, product and pipeline momentum is robust, but the company faces material pricing and market access challenges that temper the near‑term financial outlook.View all MX:NVON earnings summariesNVON Stock 12 Month Forecast
Average Price Target
$747.82
▼(-6.35% Downside)